A stem cell protein facilitates relapse of pediatric brain tumours

2022-10-28

The malignant brain tumour type medulloblastoma can become resistant to therapy which can cause relapse. Researchers at IGP have discovered a certain protein that among other things makes tumour cells resting and insensitive to radiation treatment. The research group hopes that the results could eventually lead to better treatments for children that have the highest risk to develop relapses.

Medulloblastoma is the most common form of malignant brain tumour in children, which often can be cured with operation, radiation and chemotherapy. But a distinct type of medulloblastoma has an increased risk of becoming resistant to the treatment. This will cause recurrence that is strongly connected to increased mortality.

That certain cancer cells can avoid treatment suggests there are biologic factors inside cancer cells that can enhance their resistance towards for example radiation. In the present study, the research team has shown that certain cells within the tumour bulk did not divide as often as other cancer cells did, which made them less sensitive to irradiation. They also found an accumulation of a specific protein, SOX9, in recurrent samples from patients that had been operated before and after they developed a relapse. They then suspected that SOX9 was involved in the recurrence process.

“We found that a stem cell protein called SOX9 was present with high activity in rare cells in the tumours and that cells with high activity of SOX9 were resting. SOX9 protected the resting cancer cells against radiation by temporary inhibiting another protein that otherwise promotes cell division. In experiments where we knocked out SOX9 with the CRISPR/Cas9 genetic scissors, tumour cells lost their capability to relapse, which suggests that SOX9 is important for this process,” says Fredrik Swartling, who led the study.

In animal models that resembled relapse in patients, SOX9 gave rise to increased migration and metastases of cancer cells in areas within the spinal cord. The cancer cells also became reprogrammed to avoid recognition by the immune system. These are contributing factors that might facilitate relapse.

The researchers further examined how substances that inhibited SOX9 influenced the development of relapses in animal models. Using bioinformatic analyses they discovered a few drugs that are used for other treatments that unexpectedly had a suppressing effect on SOX9 in relapses.

“We hope that our discovery could lead to more specific treatments against those SOX9 positive, slow dividing cancer cells. Eventually, it might improve the possibilities to treat children with medulloblastoma who have the highest risk of developing relapses,” says Anna Borgenvik, postdoc in Fredrik Swartling’s research group.

Anna Borgenvik performed the treatment studies based on the bioinformatic analyses developed by Holger Weishaupt, researcher in the team. Researchers at KI and at universities in Germany, USA, Canade and the UK also participated in the study, which was performed in collaboration with the Preclinical Cancer Treatment Center, a pilot facility supported by SciLifeLab and Uppsala University.

Financial support was received from the Swedish Childhood Cancer Foundation, the Swedish Cancer Society, the Swedish Research Council, the Swedish Society of Medicine, the Swedish Brain Foundation, the European Research Council - Horizon 2020, Ragnar Söderberg´s Foundation and the Worldwide Cancer Research.

More information:
Article in Cancer Research
Fredrik Swartling’s research

All new research findings from IGP

Last modified: 2022-01-26